US09061G1013
US09061G1013
BioMarin Pharmaceutical Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 10.61B EUR | 11.07B EUR | 10.92B EUR | 11.43B EUR |
Enterprise Value | 13.94B EUR | 14.4B EUR | 10.13B EUR | 10.72B EUR |
Valuation Multiples | ||||
Trailing P/E | 148.09x | 151.76x | 40.63x | 70.02x |
Forward P/E | 8.26x | -- | -- | -- |
Price to Sales | 3.11x | 3.25x | 3.37x | 4.62x |
Price to Book | 1.68x | 1.75x | 1.76x | 1.88x |
EV/Revenue | 4.09x | 4.23x | 3.13x | 4.33x |
EV/EBITDA | 21.59x | 37.34x | 21.01x | 34.6x |
Price to FCF (P/FCF) | 124.56x | 15.27x | 14.38x | 20.43x |
EV/FCF | 163.64x | 19.86x | 13.35x | 19.17x |
FCF Yield | 0.8% | 6.55% | 6.95% | 4.89% |